Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Public assessment of key performance indicators of healthcare in a Canadian province: the effect of age and chronic health problems.

Nurullah AS, Northcott HC, Harvey MD.

Springerplus. 2014 Jan 15;3:28. doi: 10.1186/2193-1801-3-28. eCollection 2014 Jan 15.

2.

Public perceptions of key performance indicators of healthcare in Alberta, Canada.

Northcott HC, Harvey MD.

Int J Qual Health Care. 2012 Jun;24(3):214-23. doi: 10.1093/intqhc/mzs012. Epub 2012 Mar 29.

PMID:
22461204
3.

Room-temperature and near-room-temperature molecule-based magnets.

Harvey MD, Crawford TD, Yee GT.

Inorg Chem. 2008 Jul 7;47(13):5649-55. doi: 10.1021/ic702359g. Epub 2008 May 23.

PMID:
18498156
4.

Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.

Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey MD, Ramsey B, Speert DP, Burns JL, Miller SI.

J Infect Dis. 2007 Oct 1;196(7):1088-92. Epub 2007 Aug 22.

5.
6.

Lack of in vitro and in vivo recognition of Francisella tularensis subspecies lipopolysaccharide by Toll-like receptors.

Hajjar AM, Harvey MD, Shaffer SA, Goodlett DR, Sjöstedt A, Edebro H, Forsman M, Byström M, Pelletier M, Wilson CB, Miller SI, Skerrett SJ, Ernst RK.

Infect Immun. 2006 Dec;74(12):6730-8. Epub 2006 Sep 18.

7.

Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility.

den Brok MW, Nuijen B, Harms R, Buluran JN, Harvey MD, Grieshaber CK, Beijnen JH.

J Oncol Pharm Pract. 2005 Mar;11(1):13-9.

PMID:
16460599
8.

Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311.

Den Brok MW, Nuijen B, Kettenes-Van Den Bosch JJ, Van Steenbergen MJ, Buluran JN, Harvey MD, Grieshaber CK, Beijnen JH.

PDA J Pharm Sci Technol. 2005 Sep-Oct;59(5):285-97.

PMID:
16316064
9.

Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form.

den Brok MW, Nuijen B, Hillebrand MJ, Grieshaber CK, Harvey MD, Beijnen JH.

J Pharm Biomed Anal. 2005 Sep 1;39(1-2):46-53.

PMID:
15899571
10.

Laser frequency locking by direct measurement of detuning.

Ratnapala A, Vale CJ, White AG, Harvey MD, Heckenberg NR, Rubinsztein-Dunlop H.

Opt Lett. 2004 Dec 1;29(23):2704-6.

PMID:
15605478
11.

Measuring entangled qutrits and their use for quantum bit commitment.

Langford NK, Dalton RB, Harvey MD, O'Brien JL, Pryde GJ, Gilchrist A, Bartlett SD, White AG.

Phys Rev Lett. 2004 Jul 30;93(5):053601. Epub 2004 Jul 26.

PMID:
15323694
12.

Absorption and fluorescence spectroscopy of rhodamine 6G in titanium dioxide nanocomposites.

Vogel R, Meredith P, Harvey MD, Rubinsztein-Dunlop H.

Spectrochim Acta A Mol Biomol Spectrosc. 2004 Jan;60(1-2):245-9.

PMID:
14670484
13.
14.

Utilization of the non-covalent fluorescent dye, NanoOrange, as a potential clinical diagnostic tool. Nanomolar human serum albumin quantitation.

Harvey MD, Bablekis V, Banks PR, Skinner CD.

J Chromatogr B Biomed Sci Appl. 2001 Apr 25;754(2):345-56.

PMID:
11339278
15.

Supplemental Content

Loading ...
Support Center